OneSource Specialty Pharma Ltd Q3 FY26 Earnings Analysis

- Significant revenue growth expected driven by multiple MSA executions and capacity expansions (Page 8). - Accelerated capacity expansion to 220 million units by end of CY 2026 to support anticipated demand (Pages 9, 16). - Expectation of eight to ten customers launching products globally in FY 2027 boosting commercial supply (Page 6). - Current capacity utilization is uncertain but expected to increase in phases through 2026 (Page 18). - Customers involved in capacity capex and reservation fees indicating strong demand and long-term partnerships (Pages 10, 16). - Confidence in capturing customer demand as capacity added progressively in phases through calendar year 2026 (Page 18). - Revenue recognition depends on regulatory approvals by customers; thus, some timing ambiguity in near term (Pages 16, 18). - Medium-term outlook supported by current capacity plans; future expansions anticipated outside India as needed (Page 9).

- Q2 FY26 showed strong revenue growth and a 37% rise in EBITDA with a 500+ bps margin expansion. - Full capacity is sold out, with an accelerated capex program to support FY27 commercialization and medium-term growth. - Mid-term outlook targets significant revenue growth, aiming for $500 million by FY28, including contributions from acquisitions. - Capacity expansions in biologics and drug-device combinations support expected demand surge. - Revenue recognition currently uncertain due to contract terms and regulatory approvals but expected to improve from FY27 onwards. - Adjusted EPS for Q2 FY26 was INR 3.9 per share on a fully diluted basis. - Positive PAT reported in Q2, improving from negative in prior year. - Long-term growth driven by capacity expansion, customer base diversification, and regulatory approvals across markets.

- OneSource Specialty Pharma is actively accelerating its Phase 2 capacity expansion to support FY ’27 commercialization plans for the DDC (drug-device combination) business. - The company is investing significantly in capital expansion, evidenced by increased net debt and prepaid high-cost debt to maintain financial discipline. - Capacity additions are planned in phases through calendar year 2026, including expansions by May/June, September/October, and end of year. - There is also an intention to expand biologics capacity beyond the current 4 kL installed, with plans to almost double it to 8 kL through limited capex. - Future capacity expansions outside India are being considered, with Warsaw operations cited as a potential site for next expansion. - Customers are contributing to capex programs or reservation fees to secure capacity in advance. - Overall, capex is focused on enabling medium-term growth and meeting increased customer demand, especially for complex products like GLP-1 injectables and biologics.

- The company is currently focused on capital expansion and has accelerated its Phase 2 capacity expansion plans for FY '27 commercialization. - Since listing in January 2025, OneSource Specialty Pharma Limited has had multiple credit rating upgrades, now in the A family, enabling financing on better terms. - The effective interest rate has improved, down 140 basis points versus prior year, now in single digits. - They have prepaid a significant amount of high-cost debt and are taking a balanced funding approach. - No explicit mention of immediate plans for new fundraising through debt or equity on page 19 or surrounding pages. - Future expansions outside India will be considered as needed, implying potential future capital needs, but no direct current fundraising announced.

- The order book for OneSource Specialty Pharma Limited's drug-device combination segment remains solid. - Nearly 8 to 10 customers are expected to launch products across multiple global markets in the next year, driving growth. - The company has 50+ active RFPs (Request for Proposals) across various modalities, including soft gelatin, injectables, and biologics, indicating a healthy pipeline. - The company continues to receive new customer engagements, including licensing agreements and MSAs. - Customers are actively participating in capital expenditure plans to secure capacity, reflecting committed demand. - Working capital is elevated due to planned inventory buildup for future DDC launches, backed by customer advances and purchase orders. - The business has noted significant BD activity and outreach in biologics with traction on new programs. - Management cautions about near-term ambiguity due to regulatory and court-related uncertainties affecting revenue recognition, despite being fully sold out on current capacity.